1.            Lavi, Y. et al. Novel Synthesis of C-Methylated Phytocannabinoids Bearing Anti-inflammatory Properties. J. Med. Chem. 66, 5536–5549 (2023).

2.            Carmon, I. et al. A Fenchone Derivative Effectively Abrogates Joint Damage Following Post-Traumatic Osteoarthritis in Lewis Rats. Cells 11, (2022).

3.            Smoum, R. et al. Fenchone Derivatives as a Novel Class of CB2 Selective Ligands: Design, Synthesis, X-ray Structure and Therapeutic Potential. Molecules 27, (2022).

4.            Aqawi, M., Sionov, R. V, Gallily, R., Friedman, M. & Steinberg, D. Anti-biofilm activity of cannabigerol against streptococcus mutans. Microorganisms 9, (2021).

5.            Kogan, N. M. et al. Novel cbg derivatives can reduce inflammation, pain and obesity. Molecules 26, (2021).

6.            Aqawi, M., Sionov, R. V, Gallily, R., Friedman, M. & Steinberg, D. Anti-Bacterial Properties of Cannabigerol Toward Streptococcus mutans. Front. Microbiol. 12, (2021).

7.            Aqawi, M. et al. Cannabigerol Prevents Quorum Sensing and Biofilm Formation of Vibrio harveyi. Front. Microbiol. 11, (2020).

8.            Gallily, R. & Yekhtin, Z. Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice. Inflammopharmacology 27, 167–173 (2019).

9.            Gallily, R., Yekhtin, Z. & Hanuš, L. O. The Anti-Inflammatory Properties of Terpenoids from Cannabis. Cannabis cannabinoid Res. 3, 282–290 (2018).

10.          Totary-Jain, H., Sionov, R. V & Gallily, R. Indomethacin sensitizes resistant transformed cells to macrophage cytotoxicity. Immunol. Lett. 176, 1–7 (2016).

11.          Fisher, T. et al. In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Curr. Oncol. 23, S15–S22 (2016).

12.          Haj, C. G. et al. HU-444, a novel, potent anti-inflammatory, nonpsychotropic cannabinoid. J. Pharmacol. Exp. Ther. 355, 66–75 (2015).

13.          Galanti, G. et al. Δ9-Tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol. (Madr). 47, 1062–1070 (2008).

14.          Weiss, L. et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 54, 244–249 (2008).

15.          Durst, R. et al. Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am. J. Physiol. - Hear. Circ. Physiol. 293, H3602–H3607 (2007).

16.          Quntar, A. A. A. A., Gallily, R., Katzavian, G. & Srebnik, M. Potent anti-inflammatory activity of 3-aminovinylphosphonates as inhibitors of reactive oxygen intermediates, nitric oxides generation, and tumor necrosis factor-alpha release. Eur. J. Pharmacol. 556, 9–13 (2007).

17.          Kogan, N. M. et al. A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol. Pharmacol. 70, 51–59 (2006).

18.          Weiss, L. et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 39, 143–151 (2006).

19.          Milman, G. et al. N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc. Natl. Acad. Sci. U. S. A. 103, 2428–2433 (2006).

20.          Ben-Shabat, S., Hanuš, L. O., Katzavian, G. & Gallily, R. New cannabidiol derivatives: Synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. J. Med. Chem. 49, 1113–1117 (2006).

21.          Moussaieff, A. et al. The Jerusalem Balsam: From the Franciscan Monastery in the old city of Jerusalem to Martindale 33. J. Ethnopharmacol. 101, 16–26 (2005).

22.          Mechoulam, R., Sumariwalla, P. F., Feldmann, M. & Gallily, R. Cannabinoids in models of chronic inflammatory conditions. Phytochem. Rev. 4, 11–18 (2005).

23.          Goldberg, S., Gallily, R., Bishara, S. & Blumenthal, E. Z. Dorzolamide-induced choroidal detachment in a surgically untreated eye. Am. J. Ophthalmol. 138, 285–286 (2004).

24.          Sumariwalla, P. F. et al. A Novel Synthetic, Nonpsychoactive Cannabinoid Acid (HU-320) with Antiinflammatory Properties in Murine Collagen-Induced Arthritis. Arthritis Rheum. 50, 985–998 (2004).

25.          Burstein, S. et al. Pain reduction and lack of psychotropic effects with ajulemic acid: Comment on the article by Sumariwalla et al [4] (multiple letters). Arthritis Rheum. 50, 4078–4079 (2004).

26.          Lodzki, M. et al. Cannabidiol - Transdermal delivery and anti-inflammatory effect in a murine model. J. Control. Release 93, 377–387 (2003).

27.          Gallily, R. et al. γ-Irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk. Lymphoma 44, 1767–1773 (2003).

28.          Mechoulam, R., Parker, L. A. & Gallily, R. Cannabidiol: An overview of some pharmacological aspects. J. Clin. Pharmacol. 42, 11S-19S (2002).

29.          Wohlman, A., Yirmiya, R., Gallily, R. & Weidenfeld, J. Effect ofmycoplasma fermentanson brain PGE2: Role of glucocorticoids and their receptors. Neuroimmunomodulation 9, 141–147 (2001).

30.          Brenner, T., Pinto, F., Abramsky, O. & Gallily, R. Inhibition of nitric oxide production for down-regulation of CNS inflammation and demyelination. Prog. Brain Res. 132, 499–506 (2001).

31.          Gallily, R., Breuer, A. & Mechoulam, R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-α production in murine macrophages, and in mice. Eur. J. Pharmacol. 406, R5–R7 (2000).

32.          Malfait, A. M. et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 97, 9561–9566 (2000).

33.          Gallily, R., Kipper-Galperin, M. & Brenner, T. Mycoplasma fermentans - Induced inflammatory response of astrocytes: Selective modulation by aminoguanidine, thalidomide, pentoxifylline and IL-10. Inflammation 23, 495–505 (1999).

34.          Trembovler, V. et al. Antioxidants attenuate acute toxicity of tumor necrosis factor-α induced by brain injury in rat. J. Interf. Cytokine Res. 19, 791–795 (1999).

35.          Yirmiya, R. et al. The role of brain cytokines in mediating the behavioral and neuroendocrine effects of intracerebral Mycoplasma fermentans. Brain Res. 829, 28–38 (1999).

36.          Schwartz, D., Engelhard, D., Gallily, R., Matoth, I. & Brenner, T. Glial cells production of inflammatory mediators induced by streptococcus pneumoniae: Inhibition by pentoxifylline, low-molecular-weight heparin and dexamethasone. J. Neurol. Sci. 155, 13–22 (1998).

37.          Haimovitz-Friedman, A. et al. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J. Exp. Med. 186, 1831–1841 (1997).

38.          Gallily, R. et al. Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J. Pharmacol. Exp. Ther. 283, 918–924 (1997).

39.          Yirmiya, R., Barak, O., Avitsur, R., Gallily, R. & Weidenfeld, J. Intracerebral administration of Mycoplasma fermentans produces sickness behavior: Role of prostaglandins. Brain Res. 749, 71–81 (1997).

40.          Shohami, E., Gallily, R., Mechoulam, R., Bass, R. & Ben-Hur, T. Cytokine production in the brain following closed head injury: Dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant. J. Neuroimmunol. 72, 169–177 (1997).

41.          Engelhard, D., Pomeranz, S., Gallily, R., Strauss, N. & Tuomanen, E. Serotype-related differences in inflammatory response to Streptococcus pneumoniae in experimental meningitis. J. Infect. Dis. 175, 979–982 (1997).

42.          Wohlman, A., Gallily, R., Yirmiya, R. & Weidenfeld, J. Characterization of the effect of mycoplasma fermentans on the hypothalamo-pituitary-adrenal axis. Neuroendocrinology 66, 221–228 (1997).

43.          Shohami, E., Bass, R., Wallach, D., Yamin, A. & Gallily, R. Inhibition of tumor necrosis factor alpha (TNFα) activity in rat brain is associated with cerebroprotection after closed head injury. J. Cereb. Blood Flow Metab. 16, 378–384 (1996).

44.          Vogt Sionov, R. & Gallily, R. Differential H-2 antigen expression in teratocarcinoma-fibroblast hybrids. Exp. Clin. Immunogenet. 12, 238–244 (1995).

45.          Rosendal, S., Frandsen, P. L., Nielsen, J. P. & Gallily, R. Pasteurella multocida toxin induces IL-6, but not IL-1 alpha or TNF alpha in fibroblasts. Can. J. Vet. Res. 59, 154–156 (1995).

46.          Messika, E. J., Avni, O., Gallily, R., Yefenof, E. & Baniyash, M. Identification and characterization of a novel protein associated with macrophage complement receptor 3. J. Immunol. 154, 6563–6570 (1995).

47.          Weidenfeld, J., Wohlman, A. & Gallily, R. Mycoplasma fermentans activates the hypothalamo-pituitary adrenal axis in the rat. Neuroreport 6, 910–912 (1995).

48.          Avron, A. & Gallily, R. Mycoplasma stimulates the production of oxidative radicals by murine peritoneal macrophages. J. Leukoc. Biol. 57, 264–268 (1995).

49.          Rosendal, S., Levisohn, S. & Gallily, R. Cytokines induced in vitro by Mycoplasma mycoides ssp. mycoides, large colony type. Vet. Immunol. Immunopathol. 44, 269–278 (1995).

50.          Brenner, T., Yamin, A. & Gallily, R. Mycoplasma triggering of nitric oxide production by central nervous system glial cells and its inhibition by glucocorticoids. Brain Res. 641, 51–56 (1994).

51.          Shohami, E., Novikov, M., Bass, R., Yamin, A. & Gallily, R. Closed head injury triggers early production of TNFα and IL-6 by brain tissue. J. Cereb. Blood Flow Metab. 14, 615–619 (1994).

52.          Caplan, S., Gallily, R. & Barenholz, Y. Characterization and purification of a mycoplasma membrane-derived macrophage-activating factor. Cancer Immunol. Immunother. 39, 27–33 (1994).

53.          Sionov, R. V & Gallily, R. Trophoblast protection of the inner cell mass from macrophage destruction. Adv. Contracept. Deliv. Syst. 10, 51–73 (1994).

54.          Brenner, T., Yamin, A., Abramsky, O. & Gallily, R. Stimulation of tumor necrosis factor-α production by mycoplasmas and inhibition by dexamethasone in cultured astrocytes. Brain Res. 608, 273–279 (1993).

55.          Sionov, R. V, Yagel, S., Har-Nir, R. & Gallily, R. Trophoblasts protect the inner cell mass from macrophage destruction. Biol. Reprod. 49, 588–595 (1993).

56.          Gallily, R., Salman, M., Tarshis, M. & Rottem, S. Mycoplasma fermentans (incognitus strain) induces TNFα and IL-1 production by human monocytes and murine macrophages. Immunol. Lett. 34, 27–30 (1992).

57.          Sionov, R. V & Gallily, R. The unique killing of embryo-derived teratocarcinoma cells by nonactivated murine macrophages is not due to a lack of H-2 antigen expression. Cell. Immunol. 142, 416–425 (1992).

58.          Pappo, I. et al. Polymyxin B reduces total parenteral nutrition-associated hepatic steatosis by its antibacterial activity and by blocking deleterious effects of lipopolysaccharide. J. Parenter. Enter. Nutr. 16, 529–532 (1992).

59.          Messika, E., Gallily, R. & Yefenof, E. Radiation leukemia virus (RadLV)‐induced leukemogenesis is associated with an increased number and activity of thymic macrophages. Int. J. Cancer 48, 924–930 (1991).

60.          Zeira, M., Gallily, R., Stein, I. & Giloh, H. Thymocyte maturation following interaction with thymus-derived macrophages. Cell. Immunol. 134, 370–377 (1991).

61.          Sher, T., Yamin, A., Rottem, S. & Gallily, R. In vitro induction of tumor necrosis factor α, tumor cytolysis, and blast transformation by Spiroplasma membranes. J. Natl. Cancer Inst. 82, 1142–1145 (1990).

62.          Zeira, M. & Gallily, R. Effect of strain and age on in vitro proliferation of murine thymus-derived macrophages. Thymus 15, 1–13 (1990).

63.          Sionov, R. V & Gallily, R. Engulfment and intracellular killing of F9 teratocarcinoma cells by non-activated murine macrophages. Int. Immunol. 2, 291–301 (1990).

64.          Sher, T., Rottem, S. & Gallily, R. Mycoplasma capricolum membranes induce tumor necrosis factor α by a mechanism different from that of lipopolysaccharide. Cancer Immunol. Immunother. 31, 86–92 (1990).

65.          Sher, T., Yamin, A., Matzliach, M., Rottem, S. & Gallily, R. Partial biochemical characterization of spiroplasma membrane component inducing tumor necrosis factor alpha. Anticancer. Drugs 1, 83–87 (1990).

66.          Yagel, S., Livni, N., Zacut, D. & Gallily, R. Characterization and localization of human placental mononuclear phagocytes by monoclonal antibodies and other cell markers. Isr. J. Med. Sci. 26, 243–249 (1990).

67.          Gifford, G. E., Loewenstein, J. & Gallily, R. Production of a Factor (CIF) from Normal Fibroblast Cells Inhibiting Tumor Necrosis Factor/Cachectin Production. Proc. Soc. Exp. Biol. Med. 191, 391–395 (1989).

68.          Gallily, R., Sher, T., Ben-Av, P. & Loewenstein, J. Tumor necrosis factor as a mediator of Mycoplasma orale-induced tumor cell lysis by macrophages. Cell. Immunol. 121, 146–153 (1989).

69.          Friedman, G. et al. Modulation of lipoprotein lipase activity in mouse peritoneal macrophages by recombinant human tumor necrosis factor. Biochim. Biophys. Acta (BBA)/Lipids Lipid Metab. 963, 201–207 (1988).

70.          Friedman, G. et al. Lipoprotein lipase in heart cell cultures is suppressed by bacterial lipopolysaccharide: an effect mediated by production of tumor necrosis factor. Biochim. Biophys. Acta (BBA)/Lipids Lipid Metab. 960, 220–228 (1988).

71.          Zeira, M. & Gallily, R. Interaction between thymocytes and thymus-derived macrophages. I. Surface components participating in mutual recognition. Cell. Immunol. 117, 264–276 (1988).

72.          Zeira, M. & Gallily, R. Interaction between thymocytes and thymus-derived macrophages. II. Engulfment of thymocytes by macrophages. Cell. Immunol. 117, 277–288 (1988).

73.          Boteach, D. & Gallily, R. Killer of virus-induced thymic lymphoma cells obtained from primary and early transfers by activated macrophages. Isr. J. Med. Sci. 24, 518–521 (1988).

74.          Yagel, S., Palti, Z. & Gallily, R. Prostaglandin E2-mediated suppression of human maternal lymphocyte alloreactivity by first-trimester fetal macrophages. Obstet. Gynecol. 72, 648–654 (1988).

75.          Loewenstein, J., Yamin, A. & Gallily, R. Establishment and characterization of murine bone marrow-derived spontaneously immortalized cell lines and clones expressing properties of normal macrophages. Exp. Hematol. 15, 685–694 (1987).

76.          Gallily, R., Gifford, G. E. & Loewenstein, J. Suppression of both macrophage-mediated tumor cell lysis and cytolytic factor production by a factor (CIF) derived from normal embryonic fibroblasts. Cancer Immunol. Immunother. 23, 60–66 (1986).

77.          Gifford, G. E., Loewenstein, J., Yamin, A. & Gallily, R. Correlation of macrophage‐mediated tumor‐cell lysis with the production of macrophage cytolytic factor (CF). preliminary characterization of a factor inhibiting cf production. Int. J. Cancer 37, 73–79 (1986).

78.          Gallily, R., Stain, I. & Zaady, O. Dual effect of lectins on macrophages: Potentiation of bacterial uptake and suppression of bactericidal activity. Immunol. Lett. 13, 151–158 (1986).

79.          Gallily, R., Stain, I. & Kornfeld, S. Non-immune non-activated chicken macrophage destroy murine fibroblast. Dev. Comp. Immunol. 9, 691–699 (1985).

80.          Gallily, R., Zeira, M. & Stain, I. Thymus-derived macrophages in long-term culture: Release of IL-1, stimulation of MLR and expression of tumoricidal activity. Immunology 55, 165–172 (1985).

81.          Axelrod, O., Mozes, E. & Gallily, R. Antigen presentation by proliferating thymic macrophages to a (T,G)-A-L specific T cell line in an H-2 restricted manner. Immunol. Lett. 10, 25–30 (1985).

82.          Cartman, G. & Gallily, R. Lysis of primitive teratocarcinoma cells by non-activated macrophages. Immunol. Lett. 10, 207–211 (1985).

83.          Loewenstein, J. & Gallily, R. Studies on the mechanism of macrophage-mediated tumor cell lysis induced by Mycoplasma orale. Isr. J. Med. Sci. 20, 895–897 (1984).

84.          Gallily, R., Vray, B., Stain, I. & Sharon, N. Wheat germ agglutinin potentiates uptake of bacteria by murine peritoneal macrophages. Immunology 52, 679–686 (1984).

85.          Davidson, S. et al. Mast cell differentiation depends on T cells and granule synthesis on fibroblasts. Immunology 48, 439–452 (1983).

86.          Loewenstein, J., Rottem, S. & Gallily, R. Induction of macrophage-mediated cytolysis of neoplastic cells by mycoplasmas. Cell. Immunol. 77, 290–297 (1983).

87.          Kunin, S. & Gallily, R. Recognition and lysis of altered-self cells by macrophages. I. Modification of target cells by 2,4,6-trinitrobenzene sulphonic acid. Immunology 48, 265–272 (1983).

88.          Gallily, R. & Savion, N. Cultivation, proliferation and characterization of thymic macrophages. Immunology 50, 139–148 (1983).

89.          Gallily, R. & Cabilly, S. Studies on the recognition of xenogeneic cells by nonimmune macrophages. II. Separate signals triggered cytostasis and cytolysis. Adv. Exp. Med. Biol. 141, 109–118 (1982).

90.          Gallily, R., Yamin, A., Caspi, R. R. & Avtalion, R. R. Non-Immunological Recognition and Killing of Xenogeneic Cells by Macrophages: III Destruction of Fish Cells by Murine Macrophages. Top. Catal. 6, 569–578 (1982).

91.          Rothlein, R., Gallily, R. & Kim, Y. B. Development of alveolar macrophages in specific pathogen-free and germ-free Minnesota miniature swine. RES J. Reticuloendothel. Soc. 30, 483–495 (1981).

92.          Gallily, R., Stain, I. & Weiss, D. W. Mouse macrophage functions under the influence of factors released by spleen cells preincubated with the methanol extraction residue (MER) tubercle bacillus fraction. Immunopharmacology 3, 221–231 (1981).

93.          Cabilly, S. & Gallily, R. Artificial binding of macrophages to syngeneic cells elicits cytostasis but not cytolysis. Immunology 42, 149–155 (1981).

94.          Bar-Eli, M., Ehrenfeld, M., Levy, M., Gallily, R. & Eliakim, M. Leukocyte chemotaxis in recurrent polyserositis (familial Mediterranean fever). Am. J. Med. Sci. 281, 15–18 (1981).

95.          Cabilly, S. & Gallily, R. Non-immunological recognition and killing of xenogeneic cells by macrophages. I. Repertoire of recognition. Immunology 44, 347–355 (1981).

96.          Cabilly, S. & Gallily, R. Non-immunological recognition and killing of xenogeneic cells by 0,23211 macrophages. II. Mechanism of killing. Immunology 44, 357–365 (1981).

97.          Levy, M., Ehrenfeld, M., Gallily, R. & Eliakim, M. Enhanced polymorphonuclear chemotaxis - A common feature of diseases responsive to colchicine. Med. Hypotheses 7, 15–20 (1981).

98.          Bar-Eli, M., Ehrenfeld, M., Litvin, Y. & Gallily, R. Monocyte function in rheumatoid arthritis. Scand. J. Rheumatol. 9, 17–23 (1980).

99.          Ehrenfeld, M., Levy, M., Bar Eli, M., Gallily, R. & Eliakim, M. Effect of colchicine on polymorphonuclear leucocyte chemotaxis in human volunteers. Br. J. Clin. Pharmacol. 10, 297–300 (1980).

100.        Schroit, A. J. & Gallily, R. Macrophage fatty acid composition and phagocytosis: Effect of unsaturation on cellular phagocytic activity. Immunology 36, 199–205 (1979).

101.        Bar-Eli, M., Levy, M., Ehrenfeld, M., Eliakim, M. & Gallily, R. Phagocyte functions in familial Mediterranean fever. Adv. Exp. Med. Biol. 121 B, 341–350 (1979).

102.        Bar-Eli, M. & Gallily, R. Age-dependent macrophage functions in New Zealand Black mice. Cell. Immunol. 45, 309–317 (1979).

103.        Bar-Eli, M., Gallily, R., Cohen, H. A. & Wahba, A. Monocyte function in psoriasis. J. Invest. Dermatol. 73, 147–149 (1979).

104.        Gallily, R. & Haran-Ghera, N. Macrophage functions in high and low cancer incidence strains of mice. A comparative study. Dev. Comp. Immunol. 3, 523–536 (1979).

105.        Bercovici, B. & Gallily, R. The cytology of the retained IUD with relation to the mechanism of action. Acta Cytol. 22, 456–459 (1978).

106.        Schwartz, M. et al. The mode of interaction with macrophages of two ordered synthetic polyeptides which differ in their thymus dependency. Immunology 35, 849–855 (1978).

107.        Wahba, A., Cohen, H. A., Bar Eli, M. & Gallily, R. Enhanced chemotactic and phagocytic activities of leukocytes in psoriasis vulgaris. J. Invest. Dermatol. 71, 186–188 (1978).

108.        Bercovici, B. & Gallily, R. The cytology of the human peritoneal fluid. Acta Cytol. 22, 124–127 (1978).

109.        Schroit, A. J. & Gallily, R. Macrophage phagocytic recognition sites. Demonstration of selectivity by hetero and alloantisera. Immunology 33, 121–127 (1977).

110.        Cabilly, S. & Gallily, R. Studies on the recognition of xenogeneic cells by nonimmune macrophages. I. Destruction of chicken fibroblasts in vitro by murine macrophages. Cell. Immunol. 29, 54–65 (1977).

111.        Gallily, R., Douchan, Z. & Weiss, D. W. Potentiation of mouse peritoneal macrophage antibacterial functions by treatment of the donor animals with the methanol extraction residue fraction of tubercle bacilli. Infect. Immun. 18, 405–411 (1977).

112.        Schroit, A. J. & Gallily, R. Quantitative in vitro phagocytic rate measurements. J. Immunol. Methods 17, 123–130 (1977).

113.        Bar-Eli, M., Gallily, R., Levy, M. & Eliakim, M. Monocyte function in familial Mediterranean fever. Am. J. Med. Sci. 274, 265–270 (1977).

114.        Gallily, R. Two macrophage - affecting agents (MER and AMS). Adv. Exp. Med. Biol. 73 PT-A, 451–452 (1976).

115.        Schroit, A. J., Rottem, S. & Gallily, R. Motion of spin-labeled fatty acids in murine macrophages relation to cellular phagocytic activity. BBA - Biomembr. 426, 499–512 (1976).

116.        Gallily, R., Yagel, S. & Weiss, D. W. Potentiated lysosomal enzyme, bacteriostatic and bactericidal activities of peritoneal macrophages of mice treated with MER fraction of tubercle bacilli. Adv. Exp. Med. Biol. 73 PT-A, 351–361 (1976).

117.        Gallily, R. & Eliahu, H. Mechanism and specificity of macrophage-mediated cytotoxicity. Cell. Immunol. 25, 245–255 (1976).

118.        Schroit, A. J., Kedar, E. & Gallily, R. A rapid and sensitive technique for the detection of Fc receptors on macrophages. J. Immunol. Methods 12, 163–170 (1976).

119.        Gallily, R. & Bar‐Eli, M. Studies on the relationships between the immunogenicity and catabolism of antigens and their binding to the surface of macrophages. Eur. J. Immunol. 6, 789–794 (1976).

120.        Gallily, R., Eliahu, H. & Ben-Ishay, Z. Macrophage killing capacity. Aspects of mechanism. Adv. Exp. Med. Biol. 66, 471–476 (1976).

121.        Gallily, R. & Ben Ishay, Z. Immune cytolysis of mouse macrophages in vitro. RES J. Reticuloendothel. Soc. 18, 44–52 (1975).

122.        Bar Eli, M. & Gallily, R. The effect of macrophage hydrolytic enzyme levels on the uptake and degradation of antigen and immune complexes. RES J. Reticuloendothel. Soc. 18, 317–328 (1975).

123.        Bar-Eli, M. & Gallily, R. Proceedings: Uptake and degradation of Ag and Ag Ab complexes by differently stimulated macrophages. Isr. J. Med. Sci. 11, 1379 (1975).

124.        Yagel, S., Gallily, R. & Weiss, D. W. Effect of treatment with the MER fraction of tubercle bacilli on hydrolytic lysozomal enzyme activity of mouse peritoneal macrophages. Cell. Immunol. 19, 381–386 (1975).

125.        Gallily, R. & Zylberlicht, D. Impairment of the bactericidal activity of murine macrophages following X-irradiation. Immunochemistry 12, 611–614 (1975).

126.        Ben-Ishay, Z., Reichert, F. & Gallily, R. Crystalline-like surface charge array of murine macrophages and lymphocytes: Visualization with cationized ferritin. J. Ultrasructure Res. 53, 119–127 (1975).

127.        Gallily, R. Allogeneic recognition and killing capacity of immune macrophages in mixed macrophage cultures (MMC). Cell. Immunol. 15, 419–431 (1975).

128.        Schroit, A. J. & Gallily, R. Studies on the binding and phagocytic inhibition properties of antimacrophage globulin (AMG). Immunology 26, 971–981 (1974).

129.        Gallily, R. & Eliahu, H. Uptake and degradation of a polypeptide antigen by stimulated and unstimulated macrophages from responder and non responder mice. Immunology 26, 603–612 (1974).

130.        Geiger, B. & Gallily, R. Surface morphology of irradiated macrophages. RES J. Reticuloendothel. Soc. 15, 274–281 (1974).

131.        Gallily, R. & Ben-Ishay, Z. Interaction between normal or irradiated macrophages and lymphocytes in mice. Cell. Immunol. 11, 314–324 (1974).

132.        Geiger, B. & Gallily, R. Effect of X irradiation on various functions of murine macrophages. Clin. Exp. Immunol. 16, 643–655 (1974).

133.        Schroit, A. J., Geiger, B. & Gallily, R. The capacity of macrophage components to inhibit anti‐macrophage serum activity. Eur. J. Immunol. 3, 354–359 (1973).

134.        Gallily, R. Uptake and degradation of a synthetic antigen by mouse macrophages containing different levels of lysosomal enzymes. Adv. Exp. Med. Biol. 29, 239–245 (1973).

135.        Geiger, B., Gallily, R. & Gery, I. The effect of irradiation on the release of lymphocyte-activating factor (LAF). Cell. Immunol. 7, 177–180 (1973).

136.        Gallily, R. & Gornostansky, M. Specificity and nature of binding of antimacrophage serum. Immunology 22, 431–439 (1972).

137.        Gallily, R. In vitro and in vivo studies of the properties and effects of antimacrophage sers (AMS). Clin. Exp. Immunol. 9, 381–391 (1971).

138.        Gallily, R., Aalseth, B. & Garvey, J. A method for increasing the number of pleural macrophages in mice. Isr. J. Med. Sci. 6, 166–167 (1970).

139.        Gallily, R. & Garvey, J. S. Prolonged antibody production in rats after single injection of KLH coated on bentonite. Immunochemistry 6, 766–767 (1969).

140.        Gallily, R. & Garvey, J. S. Primary stimulation of rats and mice with hemocyanin in soluton and adsorbed on bentonite. J. Immunol. 101, 924–929 (1968).

141.        Gallily, R. & Feldman, M. The role of macrophages in the induction of antibody in x-irradiated animals. Immunology 12, 197–206 (1967).

142.        Gallily, R., Warwick, A. & Bang, F. B. Ontogeny of macrophage resistance to mouse hepatitis in vivo and in vitro. J. Exp. Med. 125, 537–548 (1967).

143.        Gallily, R. & Feldman, M. The induction of antibody production in x-irradiated animals by macrophages that interacted with antigen. Isr. J. Med. Sci. 2, 358–361 (1966).

144.        GALLILY, R., WARWICK, A. & BANG, F. B. EFFECT OF CORTISONE OF GENETIC RESISTANCE TO MOUSE HEPATITIS VIRUS IN VIVO AND IN VITRO. Proc. Natl. Acad. Sci. U. S. A. 51, 1158–1164 (1964).

145.        Gallily, R., Shohat, B., Kalish, J., Gitter, S. & Lavie, D. Further Studies on the Antitumor Effect of Cucurbitacins. Cancer Res. 22, 1038–1045 (1962).

146.        Gitter, S., Gallily, R., Shohat, B. & Lavie, D. Studies on the Antitumor Effect of Cucurbitacins. Cancer Res. 21, 516–521 (1961).

147.        Gallily, R. & Woolley, G. W. THE HUMAN TUMOR IN THE MOUSE. Annals of the New York Academy of Sciences vol. 76 791–796 (1958).

148.        Sachs, L. & Gallily, R. The chromosomes and transplantability of tumors. ii. chromosome duplication and the loss of strain specificity in solid tumors. J. Natl. Cancer Inst. 16, 803–841 (1956).

149.        Sachs, L. & Gallily, R. The chromosomes and transplantability of tumors. iii. the transplant-ability of mouse tumors with different ce:degrees of strain specificity into previously immunized mice. J. Natl. Cancer Inst. 16, 1083–1097 (1956).

150.        Sachs, L. & Gallily, R. The chromosomes and transplantability of tumors. i. fundamental chromosome numbers and strain specificity in ascites tumors. J. Natl. Cancer Inst. 15, 1267–1289 (1955).